Topical Minocycline Gel for Inflammatory Lesions of Papulopustular Rosacea
Phase 2
- Conditions
- Interventions
- First Posted Date
- 2018-09-12
- Last Posted Date
- 2019-07-10
- Lead Sponsor
- BioPharmX, Inc.
- Target Recruit Count
- 207
- Registration Number
- NCT03667222
- Locations
- 🇺🇸
Study Center, San Antonio, Texas, United States
Open Label Phase 2 Feasibility Study of BPX-04 Topical Minocycline Gel in Rosacea
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2017-02-10
- Last Posted Date
- 2019-01-31
- Lead Sponsor
- BioPharmX, Inc.
- Target Recruit Count
- 30
- Registration Number
- NCT03050086
- Locations
- 🇺🇸
Study Center, San Diego, California, United States
Open Label Photo-Documentation Study Of BPX-01 Minocycline Gel
- First Posted Date
- 2016-10-27
- Last Posted Date
- 2022-07-26
- Lead Sponsor
- BioPharmX, Inc.
- Target Recruit Count
- 20
- Registration Number
- NCT02946788
- Locations
- 🇺🇸
Study Center, Las Vegas, Nevada, United States
BPX-01 Minocycline Topical Gel in the Treatment of Acne Vulgaris
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2016-06-28
- Last Posted Date
- 2017-04-14
- Lead Sponsor
- BioPharmX, Inc.
- Target Recruit Count
- 225
- Registration Number
- NCT02815332
BPX-01 Minocycline 1% Topical Gel for Reduction of Propionibacterium Acnes
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2016-03-15
- Last Posted Date
- 2017-09-14
- Lead Sponsor
- BioPharmX, Inc.
- Target Recruit Count
- 33
- Registration Number
- NCT02709096
- Locations
- 🇺🇸
KGL Skin Study Center, Broomall, Pennsylvania, United States
Administration of Oral Extended Release Minocycline for Assessment of Skin and Plasma Concentrations of Minocycline
- First Posted Date
- 2016-03-01
- Last Posted Date
- 2017-09-14
- Lead Sponsor
- BioPharmX, Inc.
- Target Recruit Count
- 12
- Registration Number
- NCT02695446
- Locations
- 🇺🇸
KGL Skin Study Center, Broomall, Pennsylvania, United States
A Randomized Double-blind, Placebo Controlled, Multi-center Study to Evaluate the Safety, Tolerability and Potential Effects of the Dietary Supplement Violetâ„¢ Molecular Iodine (I2) on Breast Health in Women With Cyclic Breast Discomfort and Tenderness
Not Applicable
Completed
- Conditions
- Interventions
- First Posted Date
- 2016-02-08
- Last Posted Date
- 2018-07-10
- Lead Sponsor
- BioPharmX, Inc.
- Target Recruit Count
- 31
- Registration Number
- NCT02676336
- Locations
- 🇨🇦
KGK Synergize, London, Ontario, Canada
© Copyright 2024. All Rights Reserved by MedPath